A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease | Zendy

Detlef Schuppan | Zendy; Markku Mäki | Zendy; Knut E.A. Lundin | Zendy; Jorma Isola | Zendy; Tina Friesing-Sosnik | Zendy; Juha Taavela | Zendy; Alina Popp | Zendy; Jari Koskenpato | Zendy; Jost Langhorst | Zendy; Øistein Hovde | Zendy; MarjaLeena Lähdeaho | Zendy; Stefano Fusco | Zendy; Michael Schümann | Zendy; HelgaPaula Török | Zendy; Juozas Kupčinskas | Zendy; Yurdagül Zopf | Zendy; Ansgar W. Lohse | Zendy; Mika Scheinin | Zendy; Karin Kull | Zendy; Luc Biedermann | Zendy; Valerie Byrnes | Zendy; Andreas Stallmach | Zendy; Jørgen Jahnsen | Zendy; Jonas Zeitz | Zendy; Ralf Mohrbacher | Zendy; Roland Greinwald | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

Author(s) -

Detlef Schuppan,

Markku Mäki,

Knut E.A. Lundin,

Jorma Isola,

Tina Friesing-Sosnik,

Juha Taavela,

Alina Popp,

Jari Koskenpato,

Jost Langhorst,

Øistein Hovde,

MarjaLeena Lähdeaho,

Stefano Fusco,

Michael Schümann,

HelgaPaula Török,

Juozas Kupčinskas,

Yurdagül Zopf,

Ansgar W. Lohse,

Mika Scheinin,

Karin Kull,

Luc Biedermann,

Valerie Byrnes,

Andreas Stallmach,

Jørgen Jahnsen,

Jonas Zeitz,

Ralf Mohrbacher,

Roland Greinwald

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2032441

Subject(s) - tissue transglutaminase , medicine , gastroenterology , placebo , intraepithelial lymphocyte , clinical endpoint , gluten , confidence interval , randomized controlled trial , duodenum , glutamine , immunology , pathology , immune system , enzyme , biochemistry , chemistry , alternative medicine , amino acid

In celiac disease, small intestinal transglutaminase 2 causes deamidation of glutamine residues in gluten peptides, which enhances stimulation of T cells and leads to mucosal injury. Inhibition of transglutaminase 2 is a potential treatment for celiac disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research